Haemonetics HAE Plasma — SG&A
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Haemonetics in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Haemonetics's plasma — sg&a.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Haemonetics's plasma — SG&A?
- Haemonetics (HAE) reported plasma — SG&A of $27.27M in Q1 2026.
- How has Haemonetics's plasma — SG&A changed year-over-year?
- Haemonetics's plasma — SG&A increased by 11.3% year-over-year, from $24.49M to $27.27M.
- What is the long-term trend for Haemonetics's plasma — SG&A?
- Over 3 years (2023 to 2026), Haemonetics's plasma — SG&A has grown at a -0.2% compound annual growth rate (CAGR), from $106.01M to $105.32M.
- What does plasma — SG&A mean?
- Covers the operating expenses incurred by the plasma segment for sales, marketing, and general corporate support functions. This metric reflects the overhead required to maintain and grow the segment's market presence. Investors monitor this to assess the segment's operating leverage and cost management discipline.